"Skin Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the SKIN.
| Descriptor ID |
D012878
|
| MeSH Number(s) |
C04.588.805 C17.800.882
|
| Concept/Terms |
Skin Neoplasms- Skin Neoplasms
- Neoplasms, Skin
- Neoplasm, Skin
- Skin Neoplasm
Cancer of Skin- Cancer of Skin
- Skin Cancers
- Cancer of the Skin
- Skin Cancer
- Cancer, Skin
- Cancers, Skin
|
Below are MeSH descriptors whose meaning is more general than "Skin Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Skin Neoplasms".
This graph shows the total number of publications written about "Skin Neoplasms" by people in this website by year, and whether "Skin Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 26 | 5 | 31 |
| 1995 | 32 | 4 | 36 |
| 1996 | 22 | 7 | 29 |
| 1997 | 33 | 4 | 37 |
| 1998 | 43 | 3 | 46 |
| 1999 | 29 | 5 | 34 |
| 2000 | 37 | 9 | 46 |
| 2001 | 40 | 3 | 43 |
| 2002 | 42 | 4 | 46 |
| 2003 | 66 | 12 | 78 |
| 2004 | 49 | 6 | 55 |
| 2005 | 61 | 12 | 73 |
| 2006 | 78 | 12 | 90 |
| 2007 | 69 | 6 | 75 |
| 2008 | 82 | 5 | 87 |
| 2009 | 68 | 7 | 75 |
| 2010 | 80 | 10 | 90 |
| 2011 | 103 | 9 | 112 |
| 2012 | 85 | 7 | 92 |
| 2013 | 82 | 10 | 92 |
| 2014 | 81 | 20 | 101 |
| 2015 | 82 | 10 | 92 |
| 2016 | 79 | 11 | 90 |
| 2017 | 105 | 7 | 112 |
| 2018 | 100 | 8 | 108 |
| 2019 | 76 | 6 | 82 |
| 2020 | 95 | 7 | 102 |
| 2021 | 85 | 6 | 91 |
| 2022 | 82 | 2 | 84 |
| 2023 | 66 | 2 | 68 |
| 2024 | 19 | 1 | 20 |
To return to the timeline,
click here.
Below are the most recent publications written about "Skin Neoplasms" by people in Profiles.
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. J Immunother Cancer. 2024 Mar 13; 12(3).
-
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123. Leuk Res. 2024 04; 139:107479.
-
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma. J Immunother Cancer. 2024 03 11; 12(3).
-
Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study. Oral Oncol. 2024 Apr; 151:106747.
-
Factors Influencing Patients' Confidence in Their Mohs Surgeons. Dermatol Surg. 2024 Apr 01; 50(4):381-383.
-
Polygenic risk scores, radiation treatment exposures and subsequent cancer risk in childhood cancer survivors. Nat Med. 2024 Mar; 30(3):690-698.
-
Cutaneous melanoma in older patients. BMC Geriatr. 2024 Mar 06; 24(1):232.
-
Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting. Oncology (Williston Park). 2024 03 01; 38(3):104-106.
-
Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 03; 22(2):117-135.
-
Differential Upregulation of Th1/Th17-Associated Proteins and PD-L1 in Granulomatous Mycosis Fungoides. Cells. 2024 Feb 27; 13(5).